Testing ways to safely lower steroid doses in rheumatoid arthritis
Part of Bones, joints & muscles, Immune system & allergy, Skin clinical trials.
This study compares two different schedules for reducing prednisone (a steroid) in people with rheumatoid arthritis who are also taking another standard arthritis medicine. The goal is to find the safest and most effective way to taper off steroids without causing a flare-up.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have a confirmed diagnosis of rheumatoid arthritis.
- You are currently taking both prednisone (a steroid pill) and another specific arthritis medicine (like methotrexate or a biologic) every day.
- Your prednisone dose must be either 7.5 mg per day (if you choose a fast 15-day taper) or 5 mg per day (if you choose a slow 150-day taper).
- You have not changed your arthritis medicines in the last 3 months.
- You are not pregnant and have not used steroid injections or pills for other health issues in the past year.
- You do not have certain medical conditions like adrenal insufficiency or active moderate-to-severe arthritis activity.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study follows people with rheumatoid arthritis (RA) who have achieved remission—meaning their disease is well-controlled—to see how safely doctors can reduce or stop their medications over time. You would be monitored regularly to ensure your RA stays in remission.
This trial tests an experimental drug for people with rheumatoid arthritis who have not had success with other treatments. It aims to see if the drug can help reduce joint pain and swelling.
This trial compares two ways to reduce the amount of rituximab you take: one that gradually gives it less often based on time, and another that only gives it when your disease flares up. The goal is to see which approach keeps your arthritis under control while using less medication.
This trial tests a step-by-step plan for treating rheumatoid arthritis when current medicines aren’t controlling the disease. It compares how well a targeted approach works by adjusting treatment for people who need a TNF inhibitor.
This trial studies rheumatoid arthritis (RA) patients starting or adjusting DMARD medicines and looks for signs that predict who responds best. It may help doctors choose more effective treatment sooner.
This Phase 3 study compares two ways to treat active rheumatoid arthritis: a TNF-blocking biologic versus a targeted pill treatment. It may help people who are not doing well on (or cannot tolerate) certain biologic therapies to find a better, more practical option.
Hear when a new Rheumatoid arthritis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.